UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 174

Sortiert nach

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus : Results from a controlled randomized study

Circulation (New York, N.Y.), 2005-05, Vol.111 (19), p.2525-2531

2005

Link zum Volltext

Verfügbarkeit prüfen

Effects of pioglitazone in non-diabetic patients with arterial hypertension: A double-blind, placebo-controlled study

The journal of clinical endocrinology and metabolism, 2002-12, Vol.87 (12), p.5503-5506

2002

Link zum Volltext

Verfügbarkeit prüfen

Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease

Atherosclerosis, 2008-03, Vol.197 (1), p.311-317

2008

Link zum Volltext

Verfügbarkeit prüfen

Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study

Current medical research and opinion, 2006-06, Vol.22 (6), p.1211-1215

2006

Link zum Volltext

Verfügbarkeit prüfen

Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual β-cell function: results from the PioSwitch Study

Diabetes, obesity & metabolism, 2009-05, Vol.11 (5), p.464-471

2009

Link zum Volltext

Verfügbarkeit prüfen

Visfatin: A Putative Biomarker for Metabolic Syndrome is not Influenced by Pioglitazone or Simvastatin Treatment in Nondiabetic Patients at Cardiovascular Risk - Results from the PIOSTAT Study

Hormone and metabolic research, 2007-10, Vol.39 (10), p.764-768

2007

Link zum Volltext

Verfügbarkeit prüfen

Review of the pleiotropic effects of peroxisome proliferator-activated receptor gamma agonists on platelet function

Diabetes technology & therapeutics, 2007-10, Vol.9 (5), p.410

2007

Link zum Volltext

Verfügbarkeit prüfen

Changes in insulin resistance and cardiovascular risk induced by PPARgamma activation have no impact on RBP4 plasma concentrations in nondiabetic patients

Hormone and metabolic research, 2009-03, Vol.41 (3), p.202

2009

Link zum Volltext

Verfügbarkeit prüfen

IRIS II study: the IRIS II score-assessment of a new clinical algorithm for the classification of insulin resistance in patients with Type 2 diabetes

Diabetic medicine, 2004-10, Vol.21 (10), p.1149-1153

2004

Link zum Volltext

Verfügbarkeit prüfen

The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight

Diabetes, obesity & metabolism, 2007-01, Vol.9 (1), p.132-133

2007

Link zum Volltext

Verfügbarkeit prüfen

Pioglitazon vermindert das kardiovaskuläre Risiko bei Typ-2-Diabetespatienten

Diabetologe, 2008-11, Vol.4 (7), p.542-548

2008

Link zum Volltext

Verfügbarkeit prüfen

Intermittent Complete Androgen Blockade in PSA Relapse after Radical Prostatectomy and Incidental Prostate Cancer

European urology, 1999, Vol.35 (1), p.27-31

1999

Link zum Volltext

Verfügbarkeit prüfen

Pharmacological PPARγ Stimulation in Contrast to Beta Cell Stimulation Results in an Improvement in Adiponectin and Proinsulin Intact Levels and Reduces Intima Media Thickness in Patients with Type 2 Diabetes

Hormone and metabolic research, 2005-08, Vol.37 (8), p.521-527

2005

Link zum Volltext

Verfügbarkeit prüfen

Coefficient of beta-cell failure in patients with type 2 diabetes treated with pioglitazone or acarbose

Experimental and clinical endocrinology & diabetes, 2004-02, Vol.112 (2), p.115

2004

Link zum Volltext

Verfügbarkeit prüfen

Effects of Pioglitazone in Nondiabetic Patients with Arterial Hypertension: A Double-Blind, Placebo-Controlled Study

The journal of clinical endocrinology and metabolism, 2002-12, Vol.87 (12), p.5503-5506

2002

Link zum Volltext

Verfügbarkeit prüfen

Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis

Gynecological endocrinology, 2001-06, Vol.15 (3), p.202-209

2001

Link zum Volltext

Verfügbarkeit prüfen

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control : Results from the pioneer study

Journal of the American College of Cardiology, 2005-06, Vol.45 (12), p.1925-1931

2005

Link zum Volltext

Verfügbarkeit prüfen

Fasting Intact Proinsulin Is a Highly Specific Predictor of Insulin Resistance in Type 2 Diabetes

Diabetes care, 2004-03, Vol.27 (3), p.682-687

2004

Link zum Volltext

Verfügbarkeit prüfen

Potential role of oral thiazolidinedione therapy in preserving β-cell function in type 2 diabetes mellitus

Drugs (New York, N.Y.), 2005, Vol.65 (1), p.1-13

2005

Link zum Volltext

Verfügbarkeit prüfen

Pioneer Study: PPARγ Activation Results in Overall Improvement of Clinical and Metabolic Markers Associated with Insulin Resistance Independent of Long-term Glucose Control

Hormone and metabolic research, 2005-08, Vol.37 (8), p.510-515

2005

Link zum Volltext

Verfügbarkeit prüfen

Die Relaxinexpression korreliert mit Änderungen der Fibrinogenspiegel bei Patientinnen mit Typ-2-Diabetes unter oraler antidiabetischer Therapie

Geburtshilfe und Frauenheilkunde, 2007-04, Vol.68 (4), p.348-351

2007

Link zum Volltext

Verfügbarkeit prüfen

PDB14 COST-EFFECTIVENESS OF MONO- AND COMBINATION THERAPY WITH PIOGLITAZONE COMPARED TO GLICLAZIDE IN PATIENTS WITH TYPE-2-DIABETES MELLITUS FROM A GERMAN STATUTORY HEALTH CARE PERSPECTIVE

Value in health, 2004-11, Vol.7 (6), p.739-739

2004

Link zum Volltext

Verfügbarkeit prüfen

Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis

Gynecological endocrinology, 2001, Vol.15 (3), p.202-209

2001

Link zum Volltext

Verfügbarkeit prüfen

Influence of Glucose Control and Improvement of Insulin Resistance on Microvascular Blood Flow and Endothelial Function in Patients with Diabetes Mellitus Type 2

Microcirculation (New York, N.Y. 1994), 2005-10, Vol.12 (7), p.543-550

2005

Link zum Volltext

Verfügbarkeit prüfen

Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control

Hormone and metabolic research, 2005-08, Vol.37 (8), p.510-515

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 174

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(159)
Mit Volltextzugriff
(150)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(108)
Life Sciences & Biomedicine
(78)
Humans
(53)
Biological And Medical Sciences
(49)
Medical Sciences
(34)
Animals
(31)
Physical Sciences
(31)
Female
(26)
Pharmacology & Pharmacy
(25)
Pharmacology. Drug Treatments
(25)
Aged
(24)
Chemistry
(24)
Male
(24)
Biochemistry & Molecular Biology
(19)
Middle Aged
(18)
Diabetes Mellitus, Type 2 - Drug Therapy
(16)
Fundamental And Applied Biological Sciences. Psychology
(16)
Structure-Activity Relationship
(15)
Microbiology
(13)
Chemistry, Medicinal
(12)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus : Results from a controlled randomized study

Effects of pioglitazone in non-diabetic patients with arterial hypertension: A double-blind, placebo-controlled study

Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease

Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study

Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual β-cell function: results from the PioSwitch Study

Visfatin: A Putative Biomarker for Metabolic Syndrome is not Influenced by Pioglitazone or Simvastatin Treatment in Nondiabetic Patients at Cardiovascular Risk - Results from the PIOSTAT Study

Review of the pleiotropic effects of peroxisome proliferator-activated receptor gamma agonists on platelet function

Changes in insulin resistance and cardiovascular risk induced by PPARgamma activation have no impact on RBP4 plasma concentrations in nondiabetic patients

IRIS II study: the IRIS II score-assessment of a new clinical algorithm for the classification of insulin resistance in patients with Type 2 diabetes

The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight

Pioglitazon vermindert das kardiovaskuläre Risiko bei Typ-2-Diabetespatienten

Intermittent Complete Androgen Blockade in PSA Relapse after Radical Prostatectomy and Incidental Prostate Cancer

Pharmacological PPARγ Stimulation in Contrast to Beta Cell Stimulation Results in an Improvement in Adiponectin and Proinsulin Intact Levels and Reduces Intima Media Thickness in Patients with Type 2 Diabetes

Coefficient of beta-cell failure in patients with type 2 diabetes treated with pioglitazone or acarbose

Effects of Pioglitazone in Nondiabetic Patients with Arterial Hypertension: A Double-Blind, Placebo-Controlled Study

Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control : Results from the pioneer study

Fasting Intact Proinsulin Is a Highly Specific Predictor of Insulin Resistance in Type 2 Diabetes

Potential role of oral thiazolidinedione therapy in preserving β-cell function in type 2 diabetes mellitus

Pioneer Study: PPARγ Activation Results in Overall Improvement of Clinical and Metabolic Markers Associated with Insulin Resistance Independent of Long-term Glucose Control

Die Relaxinexpression korreliert mit Änderungen der Fibrinogenspiegel bei Patientinnen mit Typ-2-Diabetes unter oraler antidiabetischer Therapie

PDB14 COST-EFFECTIVENESS OF MONO- AND COMBINATION THERAPY WITH PIOGLITAZONE COMPARED TO GLICLAZIDE IN PATIENTS WITH TYPE-2-DIABETES MELLITUS FROM A GERMAN STATUTORY HEALTH CARE PERSPECTIVE

Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis

Influence of Glucose Control and Improvement of Insulin Resistance on Microvascular Blood Flow and Endothelial Function in Patients with Diabetes Mellitus Type 2

Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control

Suchergebnisse filtern